SCHEMBL25236233

SCHEMBL25236233

O=c1[nH]ncc2sc(Br)cc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.39
PARP1 P09874 1/20 0.39
PRKCI P41743 1/20 0.39
PDE4B Q07343 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
SLC2A1 P11166 1/20 0.37
IDO1 P14902 1/20 0.33
TDO2 P48775 1/20 0.33
MKNK1 Q9BUB5 1/20 0.32
NOS1 P29475 3/20 0.32
METAP2 P50579 2/20 0.32
DYRK1A Q13627 2/20 0.32
XDH P47989 2/20 0.32
AXL P30530 1/20 0.32
CSNK2A1 P68400 1/20 0.32
LMNA P02545 1/20 0.31
TSHR P16473 1/20 0.31
ADORA2A P29274 1/20 0.31
SLC6A4 P31645 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30334708 0.70 NOS1 (0.39) ALDH1A1PARP1PRKCIPDE4BHSD17B10
SCHEMBL16044591 0.70 GSK3B (0.48) ALDH1A1
SCHEMBL1774094 0.68 PARP1 (0.43) ALDH1A1PARP1HSD17B10TDP1LMNA
SCHEMBL6198760 0.67 NOS1 (0.43) ALDH1A1TDP1IDO1NOS1METAP2
SCHEMBL7057135 0.65 ALDH1A1 (0.46) ALDH1A1PARP1PRKCIPDE4BHSD17B10
SCHEMBL7013361 0.65 ALDH1A1 (0.48) ALDH1A1PARP1PRKCIPDE4BHSD17B10
SCHEMBL25209628 0.64 KAT2B (0.34) ALDH1A1LMNASMN1; SMN2
SCHEMBL14911621 0.64 SLC2A1 (0.38) ALDH1A1PARP1PRKCIPDE4BHSD17B10
SCHEMBL15243918 0.64 ALDH1A1 (0.40) ALDH1A1PARP1PRKCIPDE4BHSD17B10
SCHEMBL12346523 0.64 PKM (0.51) ALDH1A1HSD17B10TDP1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250144094-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. 2025-05-08 US disclosed
EP-4433059-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF Erasca, Inc. (US) 2024-09-25 EP disclosed
CN-115504986-B Apoptosis signal regulating kinase inhibitor and preparation method and application thereof 江苏豪森药业集团有限公司 2024-05-14 CN disclosed
WO-2023215494-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-11-09 WO disclosed
WO-2023087027-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-05-19 WO disclosed
CN-115504986-A Apoptosis signal regulating kinase inhibitor and preparation method and application thereof 江苏豪森药业集团有限公司 2022-12-23 CN disclosed
CN-111094250-B Apoptosis signal regulating kinase inhibitor and preparation method and application thereof 江苏豪森药业集团有限公司 2022-11-04 CN disclosed
CN-111094250-A Apoptosis signal regulating kinase inhibitor and preparation method and application thereof 江苏豪森药业集团有限公司 2020-05-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250144094-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ULK1, ULK2, ULK3 ALDH1A1 3129/4885PARP1 869/4885PRKCI 1011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.